image
Healthcare - Medical - Instruments & Supplies - NYSE - CA
$ 19.68
0.562 %
$ 6.93 B
Market Cap
-18.92
P/E
1. INTRINSIC VALUE

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use.[ Read More ]

The intrinsic value of one BLCO stock under the base case scenario is HIDDEN Compared to the current market price of 19.7 USD, Bausch + Lomb Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BLCO

image
FINANCIALS
4.15 B REVENUE
10.03%
130 M OPERATING INCOME
-37.20%
-248 M NET INCOME
-1653.33%
-17 M OPERATING CASH FLOW
-4.93%
-2.11 B INVESTING CASH FLOW
-880.93%
2.08 B FINANCING CASH FLOW
2465.43%
1.2 B REVENUE
-1.64%
43 M OPERATING INCOME
7.50%
15 M NET INCOME
109.93%
154 M OPERATING CASH FLOW
957.24%
-96.9 M INVESTING CASH FLOW
-32.64%
-20 M FINANCING CASH FLOW
-50.46%
Balance Sheet Decomposition Bausch + Lomb Corporation
image
Current Assets 2.74 B
Cash & Short-Term Investments 331 M
Receivables 839 M
Other Current Assets 1.57 B
Non-Current Assets 10.7 B
Long-Term Investments 0
PP&E 1.39 B
Other Non-Current Assets 9.31 B
Current Liabilities 1.58 B
Accounts Payable 522 M
Short-Term Debt 30 M
Other Current Liabilities 1.03 B
Non-Current Liabilities 4.94 B
Long-Term Debt 4.62 B
Other Non-Current Liabilities 324 M
EFFICIENCY
Earnings Waterfall Bausch + Lomb Corporation
image
Revenue 4.15 B
Cost Of Revenue 1.64 B
Gross Profit 2.5 B
Operating Expenses 2.37 B
Operating Income 130 M
Other Expenses 378 M
Net Income -248 M
RATIOS
60.40% GROSS MARGIN
60.40%
3.14% OPERATING MARGIN
3.14%
-6.27% NET MARGIN
-6.27%
-3.80% ROE
-3.80%
-1.93% ROA
-1.93%
1.70% ROIC
1.70%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bausch + Lomb Corporation
image
Net Income -248 M
Depreciation & Amortization 382 M
Capital Expenditures -181 M
Stock-Based Compensation 74 M
Change in Working Capital -287 M
Others -75 M
Free Cash Flow -198 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bausch + Lomb Corporation
image
Wall Street analysts predict an average 1-year price target for BLCO of $22 , with forecasts ranging from a low of $18 to a high of $25 .
BLCO Lowest Price Target Wall Street Target
18 USD -8.54%
BLCO Average Price Target Wall Street Target
22 USD 11.79%
BLCO Highest Price Target Wall Street Target
25 USD 27.03%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Bausch + Lomb Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
505 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 months ago
Aug 05, 2024
Bought 505 K USD
SAUNDERS BRENT L
CEO and Chairman of the Board
+ 32250
15.661 USD
2 years ago
Jun 01, 2022
Sell 77.6 M USD
Bausch Health Companies Inc.
director:
- 4550357
17.055 USD
2 years ago
May 10, 2022
Sell 597 M USD
Bausch Health Companies Inc.
director:
- 35000000
17.055 USD
7. News
Bausch + Lomb Corporation (BLCO) Q3 2024 Earnings Call Transcript Bausch + Lomb Corporation (NYSE:BLCO ) Q3 2024 Results Conference Call October 30, 2024 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations and Business Insights Brenton Saunders - CEO & Chairman Osama Eldessouky - Executive VP & CFO Conference Call Participants Patrick Wood - Morgan Stanley Xuyang Li - Jefferies Matt Miksic - Barclays Doug Miehm - RBC Capital Markets Lilia-Celine Lozada - JPMorgan Operator Good morning and welcome to Bausch + Lomb's Third Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded. seekingalpha.com - 2 weeks ago
Bausch + Lomb (BLCO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates The headline numbers for Bausch + Lomb (BLCO) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 2 weeks ago
Bausch + Lomb (BLCO) Q3 Earnings and Revenues Top Estimates Bausch + Lomb (BLCO) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.22 per share a year ago. zacks.com - 2 weeks ago
Why Bausch + Lomb Stock Soared by Over 7% on Monday It was quite a busy and eventful day for the company. fool.com - 1 month ago
Bausch + Lomb Stock Pops as TPG, Blackstone Consider Joint Bid Bausch + Lomb Corporation (BLCO) shares popped Monday morning following reports Blackstone (BX) and TPG (TPG) are considering teaming up to buy the eyecare company. investopedia.com - 1 month ago
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio? This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the technology, construction, industrial, machinery, and financial sectors. benzinga.com - 1 month ago
Bausch + Lomb (BLCO) Surges 14.5%: Is This an Indication of Further Gains? Bausch + Lomb (BLCO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 2 months ago
Why Bausch + Lomb Rallied Today The Financial Times reported Bausch + Lomb is in talks with advisors to potentially sell itself. It had formerly sought to spin off from parent Bausch Health in a stock-for-stock deal. fool.com - 2 months ago
Bausch + Lomb Stock Jumps Amid Reports Of A Sale Bausch + Lomb (BLCO) shares popped Monday following a report that the eyecare company is considering a sale. investopedia.com - 2 months ago
Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It? Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale. investors.com - 2 months ago
Bausch & Lomb reportedly exploring sale, shares rise Bausch & Lomb stock surged on reports the American-Canadian eye health products firm is exploring a sale as it seeks to resolve issues related to its separation from its debt-laden parent company Bausch Health Cos Inc (NYSE:BHC).    According to a Financial Times report citing people familiar with the matter, Bausch & Lomb is working with Goldman Sachs to gauge interest from potential buyers. proactiveinvestors.com - 2 months ago
Bausch + Lomb Corporation (BLCO) Q2 2024 Earnings Call Transcript Bausch + Lomb Corporation (NYSE:BLCO ) Q2 2024 Earnings Call July 31, 2024 8:00 AM ET Company Participants George Gadkowski - Vice President, Investor Relations Brent Saunders - Chairman and Chief Executive Officer Sam Eldessouky - Chief Financial Officer Conference Call Participants Xuyang Li - Jefferies Patrick Wood - Morgan Stanley Craig Bijou - Bank of America Robbie Marcus - JPMorgan Douglas Miehm - RBC Capital Markets Matt Miksic - Barclays Operator Good morning, and welcome to Bausch + Lomb's Second Quarter 2024 Earnings Call. [Operator Instructions] Please note, this event is being recorded. seekingalpha.com - 3 months ago
8. Profile Summary

Bausch + Lomb Corporation BLCO

image
COUNTRY CA
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 6.93 B
Dividend Yield 0.00%
Description Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Contact 520 Applewood Crescent, Vaughan, ON, L4K 4B4 https://www.bausch.com
IPO Date May 6, 2022
Employees 13000
Officers Mr. Brenton L. Saunders J.D. Chief Executive Officer & Chairman Dr. Yehia Hashad M.D. Executive Vice President of Research & Development and Chief Medical officer Mr. Andrew Stewart President of Global Pharmaceuticals & International Consumer Mr. Alan Waterhouse CPFA, MBA Executive Vice President and Chief Supply Chain & Operations Officer Mr. Frederick J. Munsch Senior Vice President, Controller & Chief Accounting Officer Dr. Manisha A. Narasimhan Ph.D. Chief Corporate Development & Digital Officer T.J. Crawford Chief Communications Officer Mr. Jonathon L. Kellerman Chief Compliance Officer Mr. Osama A. Eldessouky Executive Vice President & Chief Financial Officer Mr. A. Robert D. Bailey Executive Vice President & Chief Legal Officer